Naturally occurring polymorphisms in HIV-1 integrase: Relationship to HIV subtype, integrase inhibitor resistance and immune selection by Tschochner, M. et al.
NATURALLY OCURRING POLYMORPHISMS IN HIV-1 INTEGRASE: 
RELATIONSHIP TO HIV SUBTYPE, INTEGRASE INHIBITOR RESISTANCE 
AND IMMUNE SELECTION 
 
Tschochner M1, Chopra A1, Maiden T1, Ahmad I1, Fordham A1, Mallal S1, 
John M1 
 
1Centre for Clinical Immunology and Biomedical Statistics, Royal Perth 
Hospital and Murdoch University, Perth, Western Australia 
 
Integrase inhibitors have emerged as an important new class of antiretroviral 
agents.  A number of resistance associated mutations have been described 
based on pre-clinical testing.  In order to determine whether viral subtype or 
HLA-specific immune selection may contribute to baseline integrase inhibitor 
resistance, we examined the prevalence of naturally occurring polymorphisms 
in the integrase sequences of 202 HIV-1 infected patients in the Western 
Australian HIV Cohort, all of whom were naïve to integrase inhibitors.  We 
further examined these changes in relation to HIV subtype, co-variation 
patterns and established associations with HLA alleles. 
 
Integrase sequences obtained by bulk sequencing and 4-digit HLA class I 
genotypes determined by sequence based typing were examined at a codon-
specific level.  The subtypes of all samples were assigned on the basis of the 
genome wide sequences using the NCBI genotyping tool. 
 
The subtype distribution in the cohort revealed 74.8% were subtype B, 4% C, 
4.5% CRF01, 0.5% CRF02, 0.5% CRF06 and 15.8% inter-subtype 
recombinants.  Residues E92, T97, F121, and Y143 were absolutely 
conserved, however at other sites the prevalence of resistance-associated 
mutations was as follows: E138K (1.2%), G140S (2.3%), V151I (2.9%), M154I 
(2.4%), N155S (0.6%), E157Q (3.6%), G163R (3.0%), Y226D (0.6%), D232N 
(0.6%).  Several residues (51, 61, 74, 125, 147, 148, 153, 183 and 230) had 
some degree of polymorphism but none that were drug resistance-associated 
changes. No sequences contained the resistance associated T125K.  
However, an alternative polymorphism T125A occurred in 35.5% of 
sequences and was dominated by non-B subtype sequences (3% of 
sequences with T125 were non-B subtypes versus 62.3% with A125).  
Notably, this polymorphism corresponds to HLA-B*5701/-B*5703 and -B*5801 
driven escape within the known SW10 epitope.  
 
In a population-based cohort, most integrase residues previously associated 
with integrase inhibitor resistance are highly conserved across and within 
HIV-1 subtypes, in keeping with being sites of significant functional, catalytic 
or structural importance. T125A appears to be subtype-specific as well as a 
result of immune selection in individuals expressing HLA-B*57/5801.  
Otherwise, the low prevalence of natural polymorphism is consistent with the 
lack of overlap between evident immune and drug targets in the integrase 
gene. 
